A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects

Clinical Pharmacokinetics

Volumn 47, Issue 12, 2008, Pages 807-816

  Yin, Ophelia Q P ^a   Wang, Yanfeng ^a   Schran, Horst ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Midostaurin, pharmacokinetics; Pharmacokinetic modelling; Population pharmacokinetics; Protein kinase C inhibitors, pharmacokinetics; Research and development

Indexed keywords

CGP 52421; CGP 62221; DRUG METABOLITE; MIDOSTAURIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; ALGORITHMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN KINASE C; STAUROSPORINE; TIME FACTORS;

EID: 56749179990     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/0003088-200847120-00005     Document Type: Article

References (30)

1. Meggio F, Donella Deana A, Ruzzene M, et al. Different susceptibility of protein kinases to staurosporine inhibition: kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 1995; 234: 317-22
2. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporine (CGP41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 1989; 43: 851-6
3. Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res 1992; 52: 5353-8
4. Fabbro D, Ruetz S, Bodis S, et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17-28
5. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60
6. Hammes HP, Lin J, Bretzel RG, et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401-6
7. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-55
8. Seo MS, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999; 154: 1743-53
9. Saishin Y, Saishin Y, Takahashi K, et al. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Invest Ophthalmol Vis Sci 2003; 44: 3656-62
10. Campochiaro PA. C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004; 45: 922-31
11. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92
12. 14C] PKC412 in healthy subjects. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2005. (Data on file)
13. Einolf HJ, Bedi Singh S. Evaluation of PKC412 and its metabolites, CGP52421 and CGP62221, to activate the human PXR in a CYP3A4 reporter gene assay. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2004. (Data on file)
14. Beal SL, Sheiner LB. NONMEM Project Group. NONMEM® users' guide. San Francisco (CA): University of California at San Francisco, 1998
15. Asimus S, Gordi T. Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model. Br J Clin Pharmacol 2006; 63: 758-62
16. Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction system. Clin Pharmacol Ther 2001; 70: 210-6
17. Gabrielsson J, Weiner D. PK/PD data analysis: concepts and applications. 2nd ed. Stockholm: Swedish Pharmaceutical Press; 1998: 450-67
18. Meibohm B, Derendorf H, Mollmann HW, et al. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther 1999; 37: 367-76
19. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
20. Lehmann JM, Mckee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23
21. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998; 95: 12208-13
22. Levy RH. Time-dependent pharmacokinetics. In: Rowland M, Tucker GT. Pharmacokinetics: theory and methodology. Oxford: Pergamon Press, 1986: 115-30
23. Warren Jr JW, Benmaman JB, Wannamaker BB, et al. Kinetics of a carbamazepine-ethosuximide interaction. Clin Pharmacol Ther 1980; 28: 646-51
24. Rostami-Hodjegan A, Wolff K, Hay AWM, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 1999; 48: 43-52
25. Von Bahr C, Steiner E, Koike Y, et al. Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther 1998; 64: 18-26
26. Boddy AV, Cole M, Pearson ADJ, et al. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995; 36: 53-60
27. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457-65
28. Russo H, Dubboin MP, Bressolle F, et al. Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients. Pharm Res 1997; 14: 1583-8
29. Hassan M, Svensson USH, Ljungman P, et al. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 1999; 48: 669-77
30. de Jonge ME, Huitema AD, Rodenhuis S, et al. Integrated population pharmaco-kinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn 2004; 31: 135-56